Neue Novavax: Anstieg nach 1:20 Re-Split

Artikel auf Englisch übersetzt:

www.ozdravotnictvi.cz/rozhovory/...viru-u-prahy-je-prioritou/


New CZ article:
(Google translation from CZ - EN)

Novavax recently purchased the Prague Vaccines production plant in Bohumil in the Prague-East district. He intends to produce the coronavirus vaccine he is currently developing here. We asked Stanley Erck, CEO and President of Novavax, for details.

In addition to the already announced production of coronavirus vaccines, is the production of vaccines against other diseases planned in the Czech Republic?

The coronavirus vaccine is currently a priority for us in Czech production. We are working so that it can be prepared and approved as soon as possible. Our main goal now is to supply a functional vaccine to the market in an adequate amount, which is up to 1 billion doses of NVX-CoV2373, our COVID-19 vaccine, per year during the full operation of our Czech plant.

Of course, Novavax is also working on the development of other vaccines, and we are currently furthest with the development of NanoFlu, our influenza vaccine, which has shown positive results in the third phase of testing. After overcoming the current pandemic, we also plan to fully return to the production of a seasonal flu vaccine, which we will fully devote to the Czech plant near Prague. In other branches of Novavax, we also work on, for example, a vaccine against respiratory syncytial virus, Ebola or malaria.

How many employees does Novavax employ in its plant near Prague? Does it plan to hire more employees in the future?

Currently, the Czech production plant for Novavax employs 150 vaccine experts, but we plan to expand their team in the future. We are currently ready to put another 100 or more new employees into operation, both in the area of ​​the production of the vaccine itself and in the area of ​​disinfection of the plant premises or maintenance of production equipment.

The European Union is now negotiating agreements with potential manufacturers of coronavirus vaccine candidates, to be acceded to by the Member States. Is Novavax involved in these negotiations and how far are they?

As can be seen from some of the recent agreements, Novavax is already working with a number of countries to obtain vaccines for their people. We will continue to report on our further negotiations.

Novavax to Participate in Upcoming Investor Conferences

Conference details are as follows:

Citi 15th Annual BioPharma Virtual Conference
Date: September 10, 2020

H.C. Wainwright 22nd Annual Global Investment Conference
Date: September 14, 2020
Time: 9:30 a.m. U.S. Eastern Time (ET)

Cantor Virtual Global Healthcare Conference
Date: September 15, 2020
Time: 11:20 a.m. U.S. Eastern Time (ET)

Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Date: September 16, 2020
Time: 12:30 p.m. U.S. Eastern Time (ET)

Leerink CyberRx Series: Vaccine Forum
Date: September 23, 2020
Time: 9:00 a.m. U.S. Eastern Time (ET)

ir.novavax.com/news-releases/...upcoming-investor-conferences